Biotechnology · Intermediate

Leveraging Big Data to Transform Drug Discovery

Written by SignalsLab

Early edition: these lessons are being reviewed.

Content

Summary

Drug repurposing leverages existing big data to identify novel indications for approved drugs, offering a faster and cheaper alternative to traditional discovery pipelines. This computational strategy integrates diverse omics and clinical data to predict therapeutic effects while addressing biases inherent in traditional clinical trials.

Intuition

Traditional drug discovery is a high-risk, expensive endeavor with low success rates and long timelines. By shifting focus to drugs already known to be safe, researchers can bypass early-stage risks and utilize vast public biomedical datasets. This approach not only accelerates the path to market but also helps correct for demographic biases often found in traditional clinical trial populations, making treatments more broadly applicable.

Derivation

  1. Traditional drug discovery has an average success rate of 9.6% and takes 12-16 years.
  2. Drug repurposing can be completed in 6 years on average at approximately USD 300 million.
  3. This represents a reduction to less than half the time and a quarter of the cost of traditional methods.
  4. Computational workflows integrate disease and chemogenomic-related gene expression data from specialized databases.
  5. Ontological resources are used to integrate these diverse data types into a cohesive analysis workflow.
  6. This method mitigates issues like biased participant selection and underrepresentation of certain racial and ethnic groups.

Worked example

Problem

Calculate the time and cost savings of repurposing thalidomide compared to traditional discovery, and identify the revenue impact.

  1. Identify traditional discovery metrics: 12-16 years and high cost.
  2. Identify repurposing metrics: 6 years and ~USD 300 million.
  3. Note that repurposing takes less than half the time and costs a quarter.
  4. Observe that thalidomide repurposing generated 75% or more of Celgene's revenue in 2016.

Answer Repurposing reduces time to under half and cost to a quarter of traditional methods. For Celgene, this strategy generated 75% or more of its 2016 revenue.

Common mistakes

  • Assuming that beneficial results from randomized controlled trials are always safe, as some were later shown to be harmful.
  • Believing that relaxing inclusion criteria in heterogeneous diseases improves study validity, when it is actually problematic.
  • Overlooking the impact of biased trial designs on the external validity of clinical decisions.

Animation

Animation coming soon

The animated version of this lesson is being prepared for the web. In the Signals AI app, lessons are drawn step by step.

Code

This is a text lesson: it has no animation code yet.

ccBYNC© 2026 SignalsLab. Lesson text shared as is under CC BY-NC 4.0.